Join us on 12-15-2022 for a live seminar about RNA SEQ
Join us on 12-15-2022 for a live seminar about RNA SEQ
We are a passionate team of scientists and engineers working from 5 research sites in 3 different countries. As our name implies, we do all our work in collaboration with our hundreds of ecosystem partners and their thousands of talented people.
Alloy is committed to supporting your career and growth goals, here and throughout our ecosystem of launched companies.
COMMUNITY
Pronoia is the irrational belief that someone is conspiring behind your back to your success. At Alloy we approach all our interactions seeking to be generous with our talents, technologies, and time. This spirit of generosity is core to our culture at Alloy and reflected in our benefits. They include comprehensive health coverage, unlimited time off, parental leave, adoption assistance, fertility support, and the continued commitment to develop you for your dream job, whether at Alloy, an 82VS company, an ecosystem partner, or any other place your life takes you.
Explore:
Our research facilities:
Boston, MA
Cambridge, UK
Basel, CH
Athens, GA
© 2023 Alloy Therapeutics, Inc. All Rights Reserved.
Thanks for your interest in our white paper, Targeting GPCRs with DeepImmune Antibody Discovery.
G protein-coupled receptors (GPCRs) play a central role in multiple physiological functions, from endocrine sensing to neurotransmission to chemotaxis of immune cells. This class has long been an attractive target for novel antibody drug discovery campaigns in multiple disease indications, but their unique nature produces many challenges for in vivo antibody discovery. In this white paper, we detail how our humanized mouse discovery platform, the ATX-Gx™, have been successfully utilized for GPCR-targeted antibody discovery, Alloy Antibody Discovery’s DeepImmune™ module builds on this robust in vivo discovery platform, coupling best-in-class immunogen production with multiple binder recovery approaches, and advanced machine-learning-based techniques for lead identification and optimization.
I’d like more material about Keyway TCR Discovery
Thanks for your interest in our recent Keyway TCRm Discovery webinar, Increasing Target Specificity and Tackling Intracellular Targets for TCRm Therapeutics Development with Keyway’s TCRm Discovery Offering. In it, the team at the helm of our TCR mimic discovery campaigns shared:
1. An overview of common challenges to intracellular protein-targeting drug discovery
2. Keyway’s industry-leading solutions to TCRm/TCR-based therapeutic discovery including its proprietary specificity screening and high-quality pMHC complex antigen production capabilities
3. A case study featuring the discovery of a panel of highly specific, functional TCRm binders against an intracellular immuno-oncology target
Upon filling out this form, you will receive an email with a link to the webinar recording.
